Regeneron Pharmaceuticals, Inc. - 10-Q Summary (Q3 2007)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2007. Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing pharmaceutical products for serious medical conditions. The company has no approved products for commercial sale and relies on collaboration agreements, licensing, and contract research for revenue. Key development programs include rilonacept (inflammatory diseases), aflibercept (oncology), and VEGF Trap-Eye (eye diseases).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2007 | Nine Months Ended Sept 30, 2007 | Balance Sheet (Sept 30, 2007) |
|---|---|---|---|
| Total Revenues | $22,311 | $60,294 | - |
| Net Loss | $(35,838) | $(92,529) | - |
| Loss Per Share (Basic/Diluted) | $(0.54) | $(1.40) | - |
| Operating Expenses | $60,978 | $163,214 | - |
| Cash & Cash Equivalents | - | - | $97,416 |
| Marketable Securities | - | - | $398,276 |
| Total Assets | - | - | $573,096 |
| Long-Term Debt (Convertible Notes) | - | - | $200,000 |
| Deferred Revenue | - | - | $193,827 |
Note: Marketable securities include $299,566 current and $98,710 non-current. Deferred revenue includes $68,814 current and $125,013 non-current.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 43% year-over-year for the quarter ($22.3M vs. $15.6M) and 14% for the nine-month period ($60.3M vs. $53.1M). This was driven primarily by new technology licensing agreements with AstraZeneca and Astellas ($10.0M recognized in Q3; $18.4M in YTD).
- Expense Increase: Operating expenses rose significantly due to expanded clinical trials. Research and Development (R&D) expenses increased 49% in the quarter ($51.7M vs. $34.8M) and 35% YTD ($136.8M vs. $101.3M). Increases were attributed to higher clinical trial costs for VEGF Trap-Eye and rilonacept, and increased headcount (639 employees in Q3 2007 vs. 557 in Q3 2006).
- Net Loss Expansion: Net loss widened to $35.8M in Q3 2007 from $27.4M in Q3 2006, and $92.5M YTD 2007 from $71.4M YTD 2006, reflecting the acceleration in R&D spending.
- Contract Manufacturing: Revenue and expenses from contract manufacturing ceased in 2007 following the expiration of the agreement with Merck in October 2006.
Guidance, Outlook, and Risks
- Clinical Milestones:
- Rilonacept: A Biologics License Application (BLA) for Cryopyrin-Associated Periodic Syndromes (CAPS) was submitted to the FDA. Priority review status was granted, with an action date extended to February 29, 2008.
- VEGF Trap-Eye: Phase 3 trials in wet AMD are underway. Positive Phase 2 results were reported in October 2007. A $20.0M milestone payment was received from Bayer HealthCare in August 2007.
- Aflibercept: Phase 3 trials in oncology (prostate and lung cancer) were initiated in Q3 2007 in collaboration with sanofi-aventis.
- Accounting Contingency: Approximately $107.9M in payments received from Bayer HealthCare (including a $75M upfront payment and $20M milestone) are currently recorded as deferred revenue. The company is formalizing global development plans to determine the appropriate revenue recognition schedule, which may result in a cumulative catch-up adjustment in a future period.
- Liquidity: The company holds approximately $497M in cash and marketable securities. Management believes this is sufficient to fund operations through early 2010, excluding the $200M convertible notes maturing in October 2008.
- Risks: Key risks include the uncertainty of clinical trial outcomes, potential failure to obtain regulatory approval, dependence on collaborators (sanofi-aventis and Bayer) for funding and commercialization, and the need for additional financing if capital is consumed faster than projected.
Investor Verification Checklist
- Deferred Revenue Recognition: Verify the timeline for formalizing the Bayer HealthCare development plan and the potential impact of the $107.9M deferred revenue catch-up on future earnings.
- Debt Maturity: Confirm the company's strategy for the $200M convertible notes maturing in October 2008 (conversion vs. refinancing vs. cash repayment).
- Rilonacept Approval: Monitor the FDA decision on the BLA for CAPS, expected by February 29, 2008, as this is the first potential commercial product.
- Burn Rate: Assess the sustainability of the current R&D burn rate (~$137M for 9 months) against the cash runway and potential future funding needs.
- Collaborator Dependence: Review the terms of the sanofi-aventis and Bayer agreements regarding termination rights and cost-sharing obligations.